Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)

Open access
Wen, Xia, Wang, Jun‐Sheng, Kivistö, Kari T., Neuvonen, Pertti J., Backman, Janne T.·2001·British Journal of Clinical Pharmacology

Abstract

Aims To evaluate the potency and specificity of valproic acid as an inhibitor of the activity of different human CYP isoforms in liver microsomes. Methods Using pooled human liver microsomes, the effects of valproic acid on seven CYP isoform specific marker reactions were measured: phenacetin O‐deethylase (CYP1A2), coumarin 7‐hydroxylase (CYP2A6), tolbutamide hydroxylase (CYP2C9), S‐mephenytoin 4′‐hydroxylase (CYP2C19), dextromethorphan O‐demethylase (CYP2D6), chlorzoxazone 6‐hydroxylase (CYP2E1) and midazolam 1′‐hydroxylase (CYP3A4). Results Valproic acid competitively inhibited CYP2C9 activity with a Ki value of 600 µ m. In addition, valproic acid slightly inhibited CYP2C19 activity (Ki = 8553 µ m, mixed inhibition) and CYP3A4 activity (Ki = 7975 µ m, competitive inhibition). The inhibition of CYP2A6 activity by valproic acid was time‐, concentration‐ and NADPH‐dependent (KI = 9150 µ m, Kinact=0.048 min−1), consistent with mechanism‐based inhibition of CYP2A6. However, minimal inhibition of CYP1A2, CYP2D6 and CYP2E1 activities was observed. Conclusions Valproic acid inhibits the activity of CYP2C9 at clinically relevant concentrations in human liver microsomes. Inhibition of CYP2C9 can explain some of the effects of valproic acid on the pharmacokinetics of other drugs, such as phenytoin. Co‐administration of high doses of valproic acid with drugs that are primarily metabolized by CYP2C9 may result in significant drug interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.0306-5251.2001.01474.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 158

Metadata

Authors
Wen, X., Wang, J., Kivistö, K. T., Neuvonen, P. J., & Backman, J. T.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2001-11
Volume
52
Issue
5
Pages
547-553
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1708423019
Cited by
158
References
1
FWCI
3.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). https://app.cochat.ai/papers/10.1046/j.0306-5251.2001.01474.x
The paper
Wen, X., Wang, J., Kivistö, K. T., Neuvonen, P. J., & Backman, J. T. (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.0306-5251.2001.01474.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.